Type 2 diabetes patients who took daily doses of empagliflozin as an add-on to metformin/sulfonylurea treatment attained greater reductions in HbA1C at six months than those in the placebo group, according to a study in Diabetes Care. Greater weight loss and improved systolic blood pressure were also seen in the empagliflozin arm compared with the control group, researchers noted.
Empagliflozin shows efficacy when added to metformin and sulfonylurea
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||